Intranasal midazolam is an effective alternative to the oral version for children undergoing dental treatments, according to a new study. Researchers found that when dentists administered the drug ...

CAMBRIDGE, England, April 26, 2017 /PRNewswire/ -- Proximagen Limited (Proximagen) today announced that its pivotal Phase 3 trial of intranasal midazolam (USL261) for the rescue treatment of seizure ...

Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

Nearly half of the children receiving intranasal midazolam for laceration repair in the emergency department (ED) exhibited extreme procedural anxiety. Younger age, reduced sociability, and extremity ...

ATLANTA, Nov. 25, 2019 /PRNewswire/ -- UCB announced today that NAYZILAM® (midazolam) nasal spray CIV will be available in retail pharmacies on December 2, 2019, for the acute treatment of ...

Proximagen announced promising data from the pivotal Phase 3 trial of USL261 (intranasal midazolam) for the rescue treatment of seizure clusters. The primary efficacy endpoint was treatment success, ...

Holsti and colleagues state that seizures lasting more than 5 minutes in the out- of-hospital setting are often treated by the patient's family. In the United States, rectal diazepam is the most ...

Objective: To evaluate the feasibility of a sedation protocol based on Lidocaine spray and Intranasal Midazolam (INM) administered by Mucosal Atomizer Device (MAD) in uncooperative children undergoing ...

About NAYZILAM1NAYZILAM® (midazolam) nasal spray CIV is a benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, ...